The site specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products.

Piramal plans to add 24,000 square feet of manufacturing space, a laboratory, a filling line, two lyophilizers, a capping machine and an external vial washer. When completed in the first quarter of 2027, the capacity of the Lexington facility will increase from currently 104 product batches per year to over 240 annual batches.

“This expansion represents a strategic investment in the future of Piramal Pharma. Filling the commercial manufacturing gap enables the Lexington site to access the rapidly expanding injectables market and establish itself as a key player in the segment,” said Nandini Piramal, chairperson of Piramal Pharma.

“The injectables market has steadily increased in recent years and there is currently insufficient supply. We are committed to adapting to meet this rising demand,” said Peter DeYoung, CEO of Piramal Global Pharma. “This expansion will significantly enhance the capacity and capabilities of our Lexington facility, positioning Piramal Pharma as a comprehensive partner across the entire product life cycle and enabling us to provide treatment solutions to more patients.”

According to Piramal, a number of clients already have committed to commercializing their products at the Lexington site following the expansion.